Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836732 | 1.00 | CXCR4 (0.36) | CXCR4LTA4HHRH3PARP1 | |
| SCHEMBL4843437 | 0.88 | CXCR4 (0.41) | CXCR4LTA4HHRH3 | |
| SCHEMBL4843426 | 0.88 | CXCR4 (0.41) | CXCR4LTA4HHRH3 | |
| SCHEMBL2917171 | 0.88 | CXCR4 (0.44) | CXCR4 | |
| SCHEMBL4836370 | 0.86 | CXCR4 (0.40) | CXCR4LTA4HHRH3 | |
| SCHEMBL4836365 | 0.86 | CXCR4 (0.40) | CXCR4LTA4HHRH3 | |
| SCHEMBL6129178 | 0.82 | — | — | |
| SCHEMBL2911134 | 0.82 | CHRNB2 (0.33) | — | |
| SCHEMBL4840715 | 0.80 | CXCR4 (0.34) | CXCR4LTA4HHRH3 | |
| SCHEMBL4840731 | 0.80 | CXCR4 (0.34) | CXCR4LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489238-B1 | PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| EP-2465857-B1 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (CH) | 2014-06-04 | — | — | EP | disclosed |
| EP-1885187-B1 | METHODS FOR TREATING DRUG RESISTANT CANCER | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2465857-A1 | Methods for synthesizing heterocyclic compounds | Novartis AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1664063-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005026177-A1 | SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | CXCR4 3781/4885LTA4H 1495/4885HRH3 4453/4885 |
| US-20060270656-A1 | Substituted piperazines of azepines, oxazepines and thiazepines | HRH4, HRH2, HRH3 | CXCR4 974/4885LTA4H 1527/4885HRH3 3/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | CXCR4 1691/4885LTA4H 4238/4885HRH3 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.